Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02319759
Recruitment Status : Completed
First Posted : December 18, 2014
Last Update Posted : March 25, 2020
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : May 31, 2016
Actual Study Completion Date : January 17, 2017
Certification/Extension First Submitted : March 7, 2017
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 August 12, 2020
August 27, 2020
2 September 21, 2020